Milan Hora

head of department

Charles University, Faculty of Medicine in Pilsen

Czech Republic

Research Interests

Explore related searches

Professors in Immunology

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Milan Hora is the Head of the Department at Charles University and University Hospital Plzeň, Czech Republic. His research primarily focuses on renal cell carcinoma and prostate cancer, as reflected in his recent publications addressing non-coding transcriptome profiles, treatment outcomes with enzalutamide and abiraterone acetate, and updates to the European Association of Urology Guidelines. His work contributes significantly to advancements in cancer diagnostics and therapeutics.

Articles (10)

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (4)

Radim Kubeš

University Hospital in Motol

CZECH REPUBLIC

View details

George Netto

University of Pennsylvania Perelman School of Medicine

UNITED STATES

View details

Ondrej Fiala

Charles University

CZECH REPUBLIC

View details

Lorenzo Marconi

Leiden University Medical Center

NETHERLANDS

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Milan Hora

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Non-coding transcriptome profiles in clear-cell renal cell carcinoma

Concomitant antihypertensive medication and outcome of patients with metastatic castration-resistant prostate cancer receiving enzalutamide or abiraterone acetate

Assessment of Prostate Carcinoma Aggressiveness: Relation to <sup>68</sup>Ga-PSMA-11-PET/MRI and Gleason Score.

Enzalutamide or Abiraterone Acetate With Prednisone in the Treatment of Metastatic Castration-resistant Prostate Cancer in Real-life Clinical Practice: A Long-term Single Institution Experience.

A tribute to Prof. Ondrej Hes, MD, PhD (1968-2022)

European Association of Urology Guidelines Panel on Renal Cell Carcinoma Update on the New World Health Organization Classification of Kidney Tumours 2022: The Urologist's Point of View.

A Renewal of the TNM Staging System for Patients with Renal Cancer To Comply with Current Decision-making: Proposal from the European Association of Urology Guidelines Panel.

The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma.

Histologic diversity in chromophobe renal cell carcinoma does not impact survival outcome: A comparative international multi-institutional study.

Collaborators (4)

Radim Kubeš

George Netto

Ondrej Fiala

Lorenzo Marconi

Make your next move.